Related Experiment Video
Updated: Jun 27, 2026

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
Linezolid Treatment for Osteomyelitis due to Staphylococcus Epidermidis with Reduced Vancomycin Susceptibility
Joon Rok Nam1, Myoung Soo Kim, Chae Heuck Lee
1Department of Neurosurgery , Seoul Paik Hospital, Inje University, College of Medicine, Seoul, Korea.
Abstract:
Limited therapeutic options are available for vancomycin intermediate-resistant Staphylococcus Epidermidis (VISE) infections and no optimum therapy has been established. We report a case of VISE skull osteomyelitis that was successfully treated with linezolid. The patient was a 53-year-old man who presented with headache, nausea and dysphasia. Brain computerized tomography (CT) demonstrated a subdural hematoma in the left hemisphere. Craniotomy and hematoma evacuation was performed and he showed good recovery despite a scalp wound infection caused by methicillin-resistant Staphylococcus aureus (MRSA). The organism isolated from the scalp wound was sensitive to vancomycin. The patient was treated with intravenous vancomycin for 44 days. However, he showed a high fever, persistent positive methicillin-resistant Staphylococcus Epidermidis (MRSE) blood cultures, and a deteriorating clinical status. He underwent infected skull bone flap removal and linezolid treatment for 35 days. During one year of follow up, he has not had any further episodes of osteomyelitis or fever. Linezolid has shown to be effective agent to eradiate osteomyelitis caused by VISE.
Related Concept Videos
Clinical Significance of Antibiotic Resistance
Acute Pyelonephritis II: Diagnostic Studies and Management
Staphylococcal Skin Infections
Mechanism of Antibiotic Resistance in MRSA
Endocarditis III: Medical Management
Inhibitors of Gram-positive Cell Wall Synthesis